Evogene
EVGN
19 hedge funds and large institutions have $38.3M invested in Evogene in 2017 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 5 increasing their positions, 2 reducing their positions, and 5 closing their positions.
150% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 2
0.27% less ownership
Funds ownership: 31.21% → 30.94% (-0.27%)
10% less funds holding
Funds holding: 21 → 19 (-2)
12% less capital invested
Capital invested by funds: $43.6M → $38.3M (-$5.31M)
40% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MCM
Moon Capital Management
New York
|
+$505K |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$382K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$373K |
| 4 |
Jane Street
New York
|
+$82.1K |
| 5 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$34.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$1.46M |
| 2 |
EVC
Eidelman Virant Capital
Saint Louis,
Missouri
|
-$163K |
| 3 |
EMG
ETF Managers Group
Summit,
New Jersey
|
-$83K |
| 4 |
NEAM
New England Asset Management
Farmington,
Connecticut
|
-$76K |
| 5 |
Morgan Stanley
New York
|
-$12.9K |
EVGN Hedge Fund Activity: Q3 2017 in Review
19 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Evogene (EVGN) for Q3 2017, worth a combined $38.3M — down 12% from $43.6M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of EVGN and 3 opened new positions — a net loss of 2 holders — while 2 trimmed existing stakes and 5 added.
The largest buyer was Moon Capital Management, adding an estimated $505K. The largest seller was Goldman Sachs, exiting entirely with an estimated $1.46M sold.
- 19 institutional investors held Evogene (EVGN) as of Q3 2017, down from 21 in Q2 2017.
- Funds reported $38.3M of Evogene stock for Q3 2017, down 12% quarter-over-quarter.
- 3 funds opened new Evogene positions in Q3 2017 and 5 closed out, a net change of -2 holders.
- The largest Evogene buyer in Q3 2017 was Moon Capital Management, an estimated $505K added.
- The largest Evogene seller in Q3 2017 was Goldman Sachs, an estimated $1.46M sold.
Based on aggregated 13F filings for Q3 2017.